Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jia Jie Biomedical Co. Ltd. currently holds a company patent portfolio with 1 pending office action. This activity is focused in the Biotechnology & Pharmaceuticals technology area. Prosecution is handled by 1 distinct examiner working within 1 distinct art unit. This indicates a singular point of contact for the company's current patent matters at the USPTO.
CRUM, MARY ABOU NADER is the busiest examiner for this portfolio, responsible for 1 pending office action. Because the total number of pending actions is 1, CRUM, MARY ABOU NADER is the sole examiner currently reviewing the company's applications. This concentration allows the applicant to focus their prosecution strategy on a single individual's preferences and requirements.
The presence of 1 distinct art unit indicates that the pending work is contained within one specialized group at the USPTO. With only 1 pending office action, the administrative volume for this portfolio is currently low. Practitioners should monitor the progress of the 1 distinct examiner to understand the likely timeline for resolution and any specific technical hurdles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771162 | Isolated Strain Of Lactic Acid Bacteria For Inhibiting Drug-Resistant Enterobacteriaceae, Lactic Acid Bacterial Composition And Synbiotic Composition Including The Same | CRUM, MARY ABOU NADER | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18771162 | Isolated Strain Of Lactic Acid Bacteria For Inhibiting Drug-Resistant Enterobacteriaceae, Lactic Acid Bacterial Composition And Synbiotic Composition Including The Same | CRUM, MARY ABOU NADER | 1657 | §103 | Final Rejection | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJia Jie Biomedical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mary Abou Nader Crum has the most, with 1 of Jia Jie Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
